Why the study?
What is the incidence and what are the risk factors for neuroleptic malignant syndrome in patients receiving antipsychotic treatment?
What is the incidence and what are the risk factors for neuroleptic malignant syndrome in patients receiving antipsychotic treatment?
The incidence of neuroleptic malignant syndrome in this Japanese psychiatric cohort was 1.8%, with high-dose haloperidol and specific clinical signs identified as risk factors.
Answers are grounded in this paper and cite their sources.
May warrant vigilance for neuroleptic malignant syndrome in agitated or malnourished patients on high-dose haloperidol; hypothesis-generating from observational data and requires prospective validation.
Between October 1981 and September 1989, 564 patients admitted to the Department of Psychiatry of the Hospital of Oita Medical University received antipsychotic treatment. Ten (1.8%) of these patients developed neuroleptic malignant syndrome. This incidence is significantly greater than that reported in a group of other studies (27/17,811, 0.2%). We compared the characteristics of this sample with known risk factors for neuroleptic malignant syndrome. It is possible that Japanese people are at an increased risk for developing neuroleptic malignant syndrome. Psychomotor excitement, refusal of food, a weight loss of greater than 1 kg per week and oral administration of haloperidol at 15 mg/day or above were found to be risk factors for developing the neuroleptic malignant syndrome.
No takes yet. Share an insight, caveat, or question.
Naganuma et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: